CDX-1140

Phase 1Small molecule

CCelldex Therapeutics

CDX-1140 is one of 45 small molecule programs targeting Breast Cancer. It is currently in Phase 1.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Breast CancerRecruiting

Biliary Tract CarcinomaRecruiting

T CellsActive, not recruiting

Breast CancerPhase 1

Recruiting

Biliary Tract CarcinomaPreclinical

Recruiting

T CellsPhase 1

Active, not recruiting

Competition

Competitive Landscape

706 competitors in Breast Cancer

#DrugCompanyPhaseTrials

Adenocard

Astellas

Preclinical

2 2

Blenoxane

Bristol-Myers Squibb

Preclinical

1 3

Methylthioninium Chloride

PProvepharm SAS

Preclinical

3 4

Duragesic

CCephalon

Preclinical

1 5

CDX-1140

CCelldex Therapeutics

Phase 1

1 6

Neoadjuvant Treatment

SShanghai Zhongshan Hospital

Preclinical

1 7

Diuretic

RReprieve Cardiovascular, Inc

Preclinical

1 8

Bisphosphonate

Amgen

Preclinical

2 9

Metfomin

UUniversity of Texas Southwestern Medical Center

Preclinical

1 10

Perflutren Lipid Microsphere

IImaRx Therapeutics

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q1 2027

Phase 1Active, not recruiting

T Cells

NCT04520711

Q2 2028

Phase 1Active, not recruiting

T Cells

NCT05349890

Q2 2042

PreclinicalRecruiting

Biliary Cancer

NCT05849480

Clinical

Trials by Indication[1]

T Cells2 trials

Personalized TCR-T: Study of Adoptively Transferred T-cell Receptor Gene-engineered T Cells (TCR-T)

Active, not recruiting·PProvidence Health & Services·Phase 1·NCT05349890·1 enrolled

Hotspot TCR-T: A Phase I/Ib Study of Adoptively Transferred T-cell Receptor Gene-engineered T Cells (TCR-T)

Active, not recruiting·PProvidence Health & Services·Phase 1·NCT04520711·24 enrolled

Breast Cancer1 trial

CD40 Agonist, Flt3 Ligand, and Chemotherapy in HER2 Negative Breast Cancer

Recruiting·UUniversity of Texas Southwestern Medical Center·Phase 1·NCT05029999·30 enrolled

Advanced Malignancies1 trial

A Study of CDX-1140 (CD40) as Monotherapy or in Combination in Patients With Advanced Malignancies

Completed·CCelldex Therapeutics·Phase 1·NCT03329950·132 enrolled

Pancreatic Ductal Adenocarcinoma1 trial

A Maintenance Therapy Study of Odetiglucan With CDX-1140 in Patients With Metastatic Pancreatic Ductal Adenocarcinoma

Terminated·HHiberCell, Inc.·Phase 1·NCT05484011·5 enrolled

Pancreatic Cancer1 trial

Immunologic Effects of CDX-301 and CDX-1140 in Resectable Pancreatic Cancer Patients

Terminated·WWashington University School of Medicine·Phase 2·NCT04536077·16 enrolled

2 more indications

Ocular Melanoma1 trial

Melanoma Vaccine Against Neoantigen and Shared Antigens by CD40 Activation and TLR Agonists In Patients With Melanoma (Including Ocular Melanoma)

Completed·CCraig L Slingluff, Jr·Phase 1/2·NCT04364230·22 enrolled

Biliary Cancer1 trial

A Phase I/II Study of CDX-1140, a CD40 Agonist, in Combination With Capecitabine and Oxaliplatin (CAPOX) and Keytruda in Subjects With Biliary Tract Carcinoma (BTC)

Recruiting·NNational Cancer Institute (NCI)·Preclinical·NCT05849480·60 enrolled

Sources

References

[1]
ClinicalTrials.gov — 8 trial records for CDX-1140. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — CDX-1140 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for CDX-1140. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Celldex Therapeutics company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 1[1]
Company: CCelldex Therapeutics

CDX-1140

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q1 2027

Q2 2028

Q2 2042

Trials by Indication[1]

T Cells2 trials

Breast Cancer1 trial

Advanced Malignancies1 trial

Pancreatic Ductal Adenocarcinoma1 trial

Pancreatic Cancer1 trial

Ocular Melanoma1 trial

Biliary Cancer1 trial

References

Drug Info

Quick Facts

Related News